Physician profile

Daniel Kaplan

San Leandro, CA

NPI 1225491632

$8,411.89

in general payments reported to CMS, 2019-2025

46 companies · $1,800 in 2025

The $1,800 reported for 2025 was more than what 93% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,873.42
Education$132.32
Gift$59.40
Long Term Medical Supply Or Device Loan$49.95
Entertainment$21.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $3,081.83 2022-2025 Minimed 780g
Novo Nordisk INC $952.27 2022-2025 Ozempic, Rybelsus, Wegovy
Amgen INC. $474.30 2020-2025 Tepezza, Repatha, Otezla
Astrazeneca Pharmaceuticals Lp $357.06 2021-2025 Breztri, Tagrisso, Calquence
Boehringer Ingelheim Pharmaceuticals, INC. $342.18 2021-2025 Jardiance
Bayer Healthcare Pharmaceuticals INC. $309.33 2022-2025
Radius Health, INC. $304.46 2023-2025 Tymlos
Mannkind Corporation $250.37 2022-2025 Afrezza
Merck Sharp & Dohme LLC $196.43 2021-2025 Keytruda, Lynparza, Welireg
Abbott Laboratories $195.62 2022-2025 Freestyle Insulinx, Freestyle Libre 3
Lilly USA, LLC $167.58 2022-2025 Mounjaro, Jardiance, Zepbound
Dexcom, INC. $165.17 2022-2025 Dexcom G6 Transmitter
Sanofi-Aventis U.S. LLC $148.86 2021-2025
Janssen Biotech, INC. $140.87 2025 Carvykti, Rybrevant, Tecvayli
Pfizer INC. $114.23 2022-2024
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Abbvie INC. $101.83 2024-2025
Springworks Therapeutics, INC. $78.12 2025 Ogsiveo
Xeris Pharmaceuticals, INC. $76.26 2024-2025 Recorlev
Astellas Pharma US INC $73.50 2025 Veozah
Madrigal Pharmaceuticals $63.03 2025 Rezdiffra
Pharmacyclics LLC, An Abbvie Company $60.02 2022-2023 Imbruvica
Novartis Pharmaceuticals Corporation $58.86 2025
Kyowa Kirin, INC. $56.12 2024 Crysvita
Ascendis Pharma Endocrinology INC $49.96 2025 Yorvipath
Ascensia Diabetes Care US INC. $48.89 2024
Glaxosmithkline, LLC. $47.12 2023 Shingrix, Arexvy
Tandem Diabetes Care, INC. $40.78 2024-2025 T:Slim X2 Insulin Pump With Control-Iq
Cequr Corporation $33.84 2023-2025 Cequr Simplicity
Integra Lifesciences Corporation $30.85 2024 Integra, Integra Dermal Regeneration Template, Primatrix
Alexion Pharmaceuticals, INC. $30.44 2023 Strensiq
Coherus Oncology, INC. $29.13 2025 Loqtorzi
Takeda Pharmaceuticals U.S.A., INC. $27.19 2023
Genmab U.S., INC. $26.44 2025 Epkinly
Insulet Corporation $25.45 2025 Omnipod
Edwards Lifesciences Corporation $24.87 2024 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Aurinia Pharma U.S., INC. $24.02 2022
Pharmacosmos Therapeutics INC. $23.91 2024 Monoferric
Tempus Ai, INC $23.66 2025 Xt Cdx
Davol INC. $22.60 2024 Phasix Mesh
Regeneron Healthcare Solutions, INC. $21.58 2024 Libtayo
Optos, INC. $21.38 2025 Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700
Progenics Pharmaceuticals, INC. $21.03 2024
Amphastar Pharmaceuticals, INC. $20.23 2025
Sequel Med Tech, LLC $19.48 2025 Twiist
Stryker Corporation $16.51 2025 Molli
Collegium Pharmaceutical, INC. $14.23 2023 Belbuca

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Kaplan

$8,411.89

in general payments reported 2019-2025

Years
2020-2025
Top company
Medtronic, INC.
Context
The $1,800 reported for 2025 was more than what 93% of providers received nationally.

https://glasscript.com/doctor/5706148/daniel-kaplan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.